Drug Profile

Bispecific IL-2/IL-13 superkine - Medicenna Therapeutics

Alternative Names: Bifunctional superKine immunotherapies - Medicenna Therapeutics; BiSKITs™; sIL2^M-Fc-sIL13^M

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medicenna Therapeutics
Class Antineoplastics; Immunotherapies; Interleukins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Regulatory T-lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Mar 2025 Preclinical development is ongoing in Cancer in USA (Parenteral) Moderna Therapeutics pipeline, March 2025
28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
10 Apr 2021 Pharmacodynamics data from preclinical studies trial in Cancer presented at the 112^th Annual Meeting of the American Association for Cancer Research (AACR-2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com